Part ofFDA →

FEDERALhearing transcript

High Impact

Congressional Hearing on FDA Foreign Drug Inspection Oversight

Original title: SECURING THE U.S. DRUG SUPPLY CHAIN: OVERSIGHT OF FDA'S FOREIGN INSPECTION PROGRAM

January 1, 2021

FDA drug safety supply chain foreign inspections public health

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

The hearing examines the effectiveness of federal oversight for foreign drug manufacturing, which directly impacts the safety and reliability of the medication supply chain for all U.S. residents.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

U.S. Patients

The safety and quality of the medications they consume depend on the effectiveness of FDA foreign inspections.

Food and Drug Administration

The agency is subject to congressional oversight regarding its inspection protocols and resource allocation.

What changed

Last recorded activity January 1, 2021.

What's next

Next step not available in the current record.

Summary

This document is a transcript of a 2019 House subcommittee hearing regarding the FDA's oversight of drug manufacturing facilities located outside the United States. Lawmakers and officials discussed the challenges of ensuring the safety and quality of medications imported from countries like India and China.

Key Facts

The hearing was held on December 10, 2019, by the Subcommittee on Oversight and Investigations.
The primary focus was the oversight of the FDA's foreign inspection program for drug manufacturing plants.
The GAO provided testimony regarding the current state of foreign drug supply chain oversight.
The FDA's Center for Drug Evaluation and Research provided testimony on their inspection processes.
Members submitted articles into the record regarding data falsification and rule-bending in drug manufacturing plants in India and China.

Why It Matters

The hearing examines the effectiveness of federal oversight for foreign drug manufacturing, which directly impacts the safety and reliability of the medication supply chain for all U.S. residents.

Frequently Asked Questions

What is the purpose of this hearing?

To review how the FDA monitors and inspects drug manufacturing facilities located in foreign countries to ensure the safety of the U.S. drug supply.

Who testified at this hearing?

Officials from the and the Food and Drug Administration (FDA).

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Increased Scrutiny on Foreign Manufacturing

The hearing highlights a shift toward greater congressional oversight of FDA inspection practices in response to reports of data integrity issues in foreign drug plants.

Food and Drug Administration Government Accountability Office

Connected Entities

personJanet Woodcock“Director, Center for Drug Evaluation and Research, FDA”Map →

organizationFood and Drug Administration“The federal agency responsible for inspecting drug manufacturing facilities”Map →

personDiana DeGette“Chair of the Subcommittee on Oversight and Investigations”Map →

personMary Denigan-Macauley“Director, Health Care, Government Accountability Office”Map →

organizationGovernment Accountability Office“The federal agency that provides auditing and investigative services to Congress”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance75
How much this matters to a regular citizen
Controversy40
Intensity of disagreement among stakeholders
Entertainment10
Compellingness for a non-policy-wonk reader
Buzz20
Current news / social attention level

Publisher tools